U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468604) titled 'Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition' on Feb. 26.
Brief Summary: Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case.
A key mechanism underlying many treatment-resistant PCC symptoms appears to be dysautonomia abnormal autonomic nervous system function driven by immune-mediated sympathetic overactivity. Persistent inflammation (cytokine storms, T/B-ce...